BBV152/BBV154 Heterologus Prime-Boost Study

PHASE2CompletedINTERVENTIONAL
Enrollment

608

Participants

Timeline

Start Date

September 1, 2021

Primary Completion Date

March 1, 2022

Study Completion Date

July 31, 2022

Conditions
Corona Virus Infection
Interventions
BIOLOGICAL

COVAXIN(BBV152)

COVAXIN® on day 0 and on day 28 via the intramuscular route in GROUP 1. COVAXIN® (Intramuscular) on day 0 and BBV154 (Intranasal) day 28:GROUP 2

BIOLOGICAL

BBV154 Intranasal Vaccine

BBV154 (Intranasal) on day 0 and COVAXIN® (Intramuscular) on day 28: GROUP 3 BBV154 on day 0 and on day 28 via the intranasal route: GROUP 4

Trial Locations (11)

110029

All India Institute of Medical Scienecs, New Delhi

500010

Malla Reddy Narayana Multispeciality Hospital, Hyderabad

Unknown

The INCLEN Trust International/Guru Nanak Hospital, Gurgaon

JSS Medical College & Hospital, Mysore

Gillurkur Multispeciality Hospital, Nagpur

Institute of Medical Sciences and SUM Hospital,Odisha, Bhubaneswar

Gleneagles Global Hospitals,Hyderabad, Hyderabad

St Theresas Hospital, Hyderabad

Prakhar Hospital Pvt Limited, Kanpur

The Medicity Hopsital, Rudrapur

Institute of Liver and Biliary Sciences,New Delhi, Delhi

All Listed Sponsors
lead

Bharat Biotech International Limited

INDUSTRY

NCT05639998 - BBV152/BBV154 Heterologus Prime-Boost Study | Biotech Hunter | Biotech Hunter